Mark - Asabys Partners

Portfolio

November 17, 2025

Agomab Announces Positive Topline Phase 2a Data for Ontunisertib in Fibrostenosing Crohn’s Disease

STENOVA trial achieves primary endpoint in 103 study participants after 12 weeks of treatment Pharmacokinetic…

Mark

Portfolio

November 4, 2025

Qida raises €37 million to continue improving the quality of life of the senior segment at home

READ THIS NEWS IN SPANISH The round is led by Quadrille Capital and co-led by…

Mark

Portfolio

October 14, 2025

Ona Therapeutics, a portfolio company of Asabys Partners and Alta Life Sciences, appoints Dr. Antoine Yver as Chair of the Board to accelerate its ADC programs towards clinical development

• Brings over 35 years of oncology drug development experience, including senior executive leadership roles…

Mark

Portfolio

October 2, 2025

AltamarCAM and Asabys agree to integrate Aliath, their life sciences unit, into Asabys

READ THIS NEWS IN SPANISH The resulting team will manage over €400M in investments in…

Mark

Portfolio

September 10, 2025

Asabys Partners Leads €10 Million Extension of SafeHeal’s Oversubscribed Series C Financing to Accelerate Commercialization of Colovac®

READ THIS NEWS IN SPANISH Asabys joins SafeHeal’s global investor syndicate, which includes Sofinnova, Solar…

Mark

Portfolio

June 11, 2025

SpliceBio Secures $135 Million Series B Financing to Advance Lead Program SB-007 in Stargardt Disease and Expand Pipeline of Genetic Medicines

READ THIS NEWS IN SPANISH Financing co-led by new investors EQT Life Sciences and Sanofi…

Mark

Portfolio

April 29, 2025

Deepull secures oversubscribed €50 million Series C financing to advance UllCORE diagnostic system for direct-from-blood rapid pathogen detection

READ THIS NEWS IN SPANISH Round co-led by Columbus Venture Partners, Panakès Partners and Mérieux…

Mark

Portfolio

April 17, 2025

Three Asabys-Backed Biotechs Featured in Nature, Showcasing Spain’s Scientific Innovation

READ THIS NEWS IN SPANISH READ THIS NEWS IN CATALAN Nature, the world's leading scientific…

Mark

Portfolio

April 1, 2025

Nuage Therapeutics appoints Dr. Stuart Hughes as CEO and Vanessa Malier as Chair

Experienced R&D leader and biotech entrepreneur, Stuart Hughes, appointed as Chief Executive Officer Life sciences…

Mark

Portfolio

March 24, 2025

Augustine Therapeutics raises oversubscribed EUR 78 million / USD 85 million Series A financing round

READ THIS NEWS IN SPANISH Novo Holdings and Jeito Capital co-led the deal, supported by…

Mark

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.

Necessary

Always Enabled

Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.

Cookie	Duration	Description
cookielawinfo-checbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Functional

Performance

Analytics

Others